Navigation Links
Lilly's Investigational GLP-1 Receptor Agonist, Dulaglutide, Showed Superior Glycemic Control Versus Comparators in Patients with Type 2 Diabetes
Date:6/22/2013

ents, was to evaluate whether dulaglutide 1.5 mg, dosed once-weekly, is non-inferior to metformin in reducing HbA1c from baseline at 26 weeks. Superiority testing was performed since the statistical criterion for non-inferiority was satisfied.

AWARD-5 was a randomized, 104 week, double-blind, placebo-controlled comparison of the effects of dulaglutide and sitagliptin on glycemic control in patients with type 2 diabetes on metformin. The primary objective of the study, conducted in 1,098 patients, was to evaluate whether dulaglutide 1.5 mg, dosed once-weekly, is non-inferior to sitagliptin in reducing HbA1c from baseline at 52 weeks. Superiority testing was performed since the statistical criterion for non-inferiority was satisfied.

About Diabetes
Approximately 25.8 million Americans[5] and an estimated 371 million people[6] worldwide have type 1 and type 2 diabetes. Type 2 diabetes is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases. Diabetes is a chronic disease that occurs when the body either does not properly produce, or use, the hormone insulin.[7]

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when Lilly introduced the world's first commercial insulin. Today Lilly works to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and a continued commitment to providing real solutions—from medicines to support programs and more—to make lives better. For more information, visit www.lillydiabetes.com.

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
2. Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
3. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
4. Upsher-Smith Currently Recruiting People With Epilepsy To Evaluate Investigational Rescue Treatment For Seizure Clusters
5. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
6. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
7. Can a genetic variation in the vitamin D receptor protect against osteoporosis?
8. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
9. Receptos Co-Publishes Highest Resolution G-Protein Coupled Receptor Structure to Date in Science
10. Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science
11. Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... , March 30, 2015 ... biological drugs to treat cancer, viral infections and ... Sir John Bell , the Regius Professor ... the Office for the Strategic Coordination of Health ... effect.      (Photo: http://photos.prnewswire.com/prnh/20150330/736483 ...
(Date:3/30/2015)... and MADISON, Wis. , March ... Nakajima ,) (TSE: 4901) ("Fujifilm") and Cellular Dynamics International, ... ICEL ) ("CDI"), a leading developer and manufacturer of ... specifications, today announced that the two companies have entered ... via an all-cash tender offer to be followed by ...
(Date:3/29/2015)... Texas , March 29, 2015 /PRNewswire/ ... presentation of important study data showing the ... in 1,599 gynecologic cancer samples. Using Caris ... profiling service, researchers identified expression of programmed ... cancers independent of histology while its ligand ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 The consumption ... back of the recession and high prices in 2008. ... has recovered and keeps on gaining momentum now. , ... stands at more than 100,000 thousand tonnes. No considerable ... Meantime, the global capacity rocketed during 2012-2013, registering 11% ...
Breaking Biology Technology:Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 2Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 4Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 6Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 7Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 8Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3
... 27, 2008 - Vol. 299. No. 8: ,Venous Thromboembolism ... Administration for the Treatment of ... Biotech believes that,the conclusions of a study published in ... American Medical Association (JAMA) by Bennett, et al, do,not ...
... Colo., Feb. 26 Replidyne, Inc.,(Nasdaq: RDYN ) today ... ended December 31, 2007., Replidyne reported a net loss ... or a net loss per basic and diluted common share,of ... million, or $0.36 per,basic and diluted common share, for the ...
... Firms Recommend Pharmion ... merger with Celgene Special Meeting ... Corp. Urges All Shareholders to Vote FOR the Proposed Merger, ... ) today announced that Institutional Shareholder Services,(ISS) has recommended that ...
Cached Biology Technology:Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 2Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 3Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 4Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 5Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 6Replidyne Announces 2007 Fourth Quarter and Full Year Results 2Replidyne Announces 2007 Fourth Quarter and Full Year Results 3Replidyne Announces 2007 Fourth Quarter and Full Year Results 4Replidyne Announces 2007 Fourth Quarter and Full Year Results 5Replidyne Announces 2007 Fourth Quarter and Full Year Results 6Replidyne Announces 2007 Fourth Quarter and Full Year Results 7ISS Recommends Pharmion Shareholders Vote for Merger With Celgene 2ISS Recommends Pharmion Shareholders Vote for Merger With Celgene 3
(Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/48tj8z/global_biometrics ... "Global Biometrics Market Forecast and Opportunities, 2020" ... for biometric authentication systems is projected to grow ... The driving forces for this highly ... projects and constant development in technology. In 2014, ...
(Date:3/2/2015)... JOSE, Calif. , March 2, 2015 /PRNewswire/ ... the leading developer of human interface solutions, today ... technology that is designed to enable rapid and ... Natural ID™ module for gaming is a turnkey ... ODMs the ability to quickly integrate fingerprint ID ...
(Date:3/2/2015)... VILNIUS, Lithuania , March 2, 2015   ... AI technologies, today introduced the SentiGaze Software Development ... developers to create applications that use off-the-shelf webcams to ... a user gazes at a monitor. Heatmaps can be ... determining the effectiveness of online advertising. The SDK can ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... a new location or go extinct as a result of ... Northern England seem to defy the odds and adapt to ... study by scientists from Syracuse University and the University of ... of the Early Edition of the Proceedings of the ...
... -- The Soil Science Society of America (SSSA) applauds ... his colleagues in the Senate who helped usher in ... placing soil on par with water and air. ... Senators Kent Conrad (D-ND), Charles Grassley (R-IA), Russ Feingold ...
... lenses are joining the trend to go green. Chemical ... fluid found in our bodies can be used as a ... step up from the current wave of self-moisturizing contact lenses ... eye dryness and increase wearer comfort. It is estimated ...
Cached Biology News:New study finds that some plants can adapt to widespread climate change 2Senate resolution shines spotlight on the importance of soils 2Self-moisturizing contact lenses, naturally 2
ABI 432 Resins • Gln(Trt) Peptide Synthesis Column...
The E. coli Expression System with Gateway Technology is designed to create E. coli expression clones containing the T7 promoter. The expression clones are ready for transformation and expression in ...
...
Human RUNX2/CBFA1 MAb (Clone 232902)...
Biology Products: